SARS-CoV-2 immune response
Recruiting
- Conditions
- COVID-1910047438
- Registration Number
- NL-OMON55057
- Lead Sponsor
- Diakonessenhuis Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 800
Inclusion Criteria
Before and after COVID-19 vaccination
Exclusion Criteria
< 18 years old
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To determine both T- and B-cell responses in COVID-19 patients.</p><br>
- Secondary Outcome Measures
Name Time Method <p>• To determine the capability of the SARS-CoV-2 ELISpot to detect patients with<br /><br>a wide range of clinical manifestations with COVID-19<br /><br>• To determine the dynamics in T-cell and B-cell response in time in COVID-19<br /><br>patients<br /><br>• To determine differences in immune responses in severe, moderate and mild<br /><br>disease<br /><br>• To relate lineage strain diversity to disease and immune response<br /><br>• To determine biomarkers linked to development of severe, moderate or mild<br /><br>disease<br /><br>• To determine factors for (the development) of immunity to COVID-19</p><br>